|

Trabectedin Clinical Trials

7 actively recruiting trials across 1 location

Also known as: Dacarbazine, Gemcitabine, Trabectedin arm, Yondelis

Pipeline

Phase 2: 4Phase 3: 1Phase 1/2: 2

Top Sponsors

Sarcoma Oncology Research Center, LLC2
Italian Sarcoma Group2
Universität Münster1
UNICANCER1
Grupo Espanol de Investigacion en Sarcomas1

Indications

Cancer7
Leiomyosarcoma2
Soft Tissue Sarcoma2
Leiomyosarcoma of Ovary1
Liposarcoma, Myxoid1

Other5 trials

Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour

Phase 2

Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma

Phase 2

Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients

Phase 1/2

Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma

Phase 2

tTF-NGR Randomized Study - STS

Phase 3

Santa Monica, California2 trials

Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma

Sant P Chawla

Phase 2

SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma

Sarcoma Oncology Research Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.